Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × ridaforolimus × Other solid neoplasm × Clear all

Phase

Status

Completed 2 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2 Other solid neoplasm 1 Gynecologic 1 Gastrointestinal 1

Conditions

Interventions

pembrolizumab 23 Cisplatin 15 Pemetrexed 14 Paclitaxel 14 Carboplatin 14 Cyclophosphamide 9 Docetaxel 8 Nivolumab 7 atezolizumab 6 Injections 5 Gemcitabine 5 Filgrastim 5 olaparib 4 durvalumab 4 aldesleukin 4 Melphalan 4 Leucovorin 4 Irinotecan 4 Granulocyte Colony-Stimulating Factor 4 Etoposide 4 Bevacizumab 4 spartalizumab 3 liposomal doxorubicin 3 fludarabine 3 epacadostat 3 defactinib 3 adavosertib 3 Thiotepa 3 Ramucirumab 3 Radiotherapy, Intensity-Modulated 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01431534 2019-03-01

MK-8669-056

Merck Sharp & Dohme LLC

Phase 1 Terminated

20 enrolled 10 charts

Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡